Does Insurance Cover Tirzepatide? What You Need to Know in 2026

*This article is for informational purposes only. It is not medical advice. Consult a licensed healthcare provider before starting any medication or treatment program.*

---

The short answer: it depends entirely on which version of tirzepatide you take and why.

Tirzepatide is the same active compound sold under two different brand names for two different FDA-approved indications. Mounjaro is approved for type 2 diabetes management. Zepbound is approved for chronic weight management in adults with obesity or overweight with a weight-related health condition. Insurance treats these two indications very differently, and the gap is substantial.

If you have type 2 diabetes and your doctor prescribes Mounjaro, most commercial insurance plans will cover it, typically with prior authorization requirements. If you are seeking tirzepatide for weight loss specifically, you are navigating a coverage landscape where most plans still exclude anti-obesity medications entirely.

This guide walks through exactly how tirzepatide insurance coverage works in 2026: what Medicare and Medicaid cover, what commercial plans require, how to handle a prior authorization, what the Eli Lilly savings programs offer, and what options exist when insurance will not pay.

---

Mounjaro vs. Zepbound: Why the Distinction Matters for Coverage

Understanding tirzepatide coverage starts with understanding why Mounjaro and Zepbound, which contain the same medication, are treated so differently by insurers.

Mounjaro (tirzepatide for type 2 diabetes): Mounjaro received FDA approval in 2022 for improving blood sugar control in adults with type 2 diabetes. It works through a dual mechanism, activating both GIP and GLP-1 receptors in a way that improves insulin sensitivity, reduces glucagon release, and slows gastric emptying. In the SURPASS-1 trial ([PMID: 34186022](https://pubmed.ncbi.nlm.nih.gov/34186022/)), tirzepatide reduced HbA1c by up to 2.0 percentage points from baseline compared to placebo, a clinically meaningful improvement in blood sugar control. Because diabetes is a condition that commercial insurance routinely covers, Mounjaro is on most major health plan formularies when prescribed for T2D.

Zepbound (tirzepatide for weight management): Zepbound received FDA approval in November 2023 for chronic weight management. It is the same tirzepatide molecule, but prescribed for a different indication and subject to the same coverage barriers that affect all anti-obesity medications. In the SURMOUNT-1 trial ([PMID: 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)), participants taking tirzepatide 15mg lost an average of 22.5 percent of body weight over 72 weeks. Despite this efficacy, the insurance coverage picture for Zepbound remains difficult.

The off-label workaround does not work: Some patients wonder whether their doctor could prescribe Mounjaro instead of Zepbound for weight loss, since the medication is identical. Insurers watch for this. Most plans will deny or rescind Mounjaro coverage if they identify the prescription is being used for weight management rather than diabetes management in a patient without a documented T2D diagnosis. This is not a reliable path around the coverage gap.

---

Commercial Insurance Coverage for Tirzepatide in 2026

For employer-sponsored and commercial health plans, coverage of Zepbound for weight management remains limited and inconsistent.

Research published in *Health Affairs* ([DOI: 10.1377/hlthaff.2023.01057](https://www.healthaffairs.org/doi/10.1377/hlthaff.2023.01057)) found that fewer than 30 percent of large employer health plans covered anti-obesity medications as of 2023. That share has grown as employer awareness has increased, but the majority of commercial plans still exclude anti-obesity medications entirely or impose conditions that make access genuinely difficult.

Mounjaro for T2D is generally covered. Zepbound for weight management is where the friction starts.

When a commercial plan does include Zepbound, it typically requires:

• Prior authorization. Your provider must document medical necessity before the insurer approves the prescription. This includes your BMI, any weight-related comorbidities, and often a history of prior weight management efforts.
• BMI thresholds. Most plans align with FDA eligibility criteria: BMI of 30 or higher, or BMI of 27 or higher with a documented comorbidity such as type 2 diabetes, hypertension, sleep apnea, or cardiovascular disease.
• Step therapy. Some plans require documentation that you have attempted other weight loss medications or formal structured programs before approving a GLP-1 medication.
• Specialty tier placement. Even when covered, Zepbound is typically placed on a specialty tier with higher cost-sharing. Post-deductible out-of-pocket costs of $200 to $500 per month are common.

Plan formularies change annually. Coverage you have in one plan year may not carry over to the next. If you are comparing job offers or open enrollment options, checking each plan's formulary for Zepbound specifically is worth the time.

---

Medicare Coverage for Tirzepatide

Medicare coverage of tirzepatide in 2026 depends sharply on which indication is involved.

Mounjaro under Medicare Part D: Mounjaro is approved for type 2 diabetes, and Medicare Part D covers it for that indication across most Part D plans, though formulary placement and cost-sharing vary by plan. If you have Medicare and T2D, Mounjaro is generally accessible. Monthly out-of-pocket costs under Part D will depend on your specific plan, whether you have reached your annual deductible, and which coverage phase you are in.

Zepbound under Medicare Part D: This is where the situation is meaningfully different from semaglutide. Medicare Part D was historically prohibited from covering drugs used "for weight loss" under the Social Security Act. That exclusion still applies to Zepbound for most Medicare beneficiaries in 2026.

For context: Wegovy (semaglutide for weight management) received a specific FDA label update for cardiovascular risk reduction in March 2024, following results from the SELECT trial showing a 20 percent reduction in major cardiovascular events. That label update allowed CMS to clarify that Part D plans may cover Wegovy for established cardiovascular disease patients under the cardiovascular indication.

Tirzepatide's situation differs. SURPASS-CVOT ([PMID: 41406444](https://pubmed.ncbi.nlm.nih.gov/41406444/)), published in December 2025, demonstrated that tirzepatide was noninferior to dulaglutide for cardiovascular outcomes across 13,299 patients with type 2 diabetes and high cardiovascular risk. That is an important safety finding. However, SURPASS-CVOT was designed as a noninferiority trial against an active comparator, not a placebo-controlled superiority trial for primary MACE reduction. A specific cardiovascular risk reduction label for Zepbound had not been issued as of early 2026, and CMS coverage expansion parallel to what occurred with Wegovy had not been established for Zepbound.

In practical terms: Medicare beneficiaries seeking tirzepatide specifically for weight management remain largely uncovered under Part D as of 2026.

Medicare Advantage: Some Medicare Advantage plans (Part C) have voluntarily added coverage for anti-obesity medications. Coverage varies significantly by plan and region. Check your specific plan's formulary annually, as these decisions can change.

---

Medicaid Coverage: A State-by-State Situation

Medicaid coverage of anti-obesity medications varies by state, with no federal requirement for coverage.

A limited number of states have moved toward including GLP-1 medications for weight management in their Medicaid programs. Most have not, or impose eligibility requirements that narrow access significantly. Medicaid formularies also change with state budget cycles, so coverage in one year does not guarantee coverage in the next.

If you are on Medicaid, contact your state's program directly or ask your prescribing provider to verify your specific plan's formulary. Do not assume coverage based on a neighboring state's policy or what you read in an article from a prior year.

For Mounjaro with a T2D diagnosis, Medicaid coverage is generally more available, though prior authorization requirements still apply in many states.

---

Navigating Prior Authorization

Prior authorization is the process where your insurer reviews and approves a medication before the pharmacy will fill it at the covered price. For tirzepatide, this is standard even in plans that do cover it.

What your provider typically needs to submit for a tirzepatide prior authorization:

• Documentation of your BMI and current weight history
• A statement of medical necessity explaining why tirzepatide is the appropriate treatment
• Any weight-related comorbidities such as hypertension, sleep apnea, or cardiovascular disease
• Evidence of prior interventions if your plan requires step therapy, this may include prior weight loss medications tried, participation in structured programs, or documented lifestyle counseling
• Lab work in some cases, including baseline metabolic panels or HbA1c results

Standard prior authorizations can take 14 to 30 days. Urgent reviews may be decided within 72 hours for patients with acute clinical need.

If your initial request is denied, you have the right to appeal. Ask your provider to submit a detailed letter of medical necessity with supporting clinical documentation. Many denials are overturned on first appeal when providers advocate actively with additional evidence.

The step most patients skip: Begin the prior authorization process before assuming it will fail. Many patients give up before submitting the initial request. If your provider has experience submitting GLP-1 authorizations, they often have documentation templates that meaningfully improve approval rates.

---

Eli Lilly Savings Programs

Eli Lilly, the manufacturer of Mounjaro and Zepbound, offers patient assistance programs for both medications. These are worth understanding before abandoning the brand-name route.

Zepbound savings card: Eli Lilly offers a savings card program for commercially insured patients that can reduce the monthly cost of Zepbound significantly. Eligibility requirements and offer terms change periodically. The savings card is specifically not available to patients covered by government insurance programs, including Medicare and Medicaid.

Mounjaro savings card: A similar savings program exists for Mounjaro for commercially insured T2D patients. Same eligibility restrictions apply.

Patient assistance programs: For patients who are uninsured and below income thresholds, Eli Lilly's Lilly Cares Foundation offers programs that may provide Mounjaro or Zepbound at no cost or reduced cost. These programs have income requirements and require applying directly through Eli Lilly's patient support resources.

Check the official Eli Lilly patient support program for current terms and eligibility criteria before making coverage decisions based on these programs.

---

HSA and FSA Eligibility

If you pay out of pocket for tirzepatide or compounded tirzepatide, you may be able to use a Health Savings Account (HSA) or Flexible Spending Account (FSA) to cover the cost with pre-tax dollars.

Prescription medications are generally eligible HSA and FSA expenses under IRS rules, provided they are prescribed by a licensed healthcare provider. This applies to both brand-name and compounded medications when legitimately prescribed.

Compounded tirzepatide prescribed through a licensed telehealth provider for a medical indication such as obesity or overweight with comorbidities is generally an eligible expense. Confirm with your plan administrator or benefits provider before submitting, as rules can vary by employer plan.

Using an HSA or FSA effectively reduces the real cost of treatment by 22 to 37 percent depending on your marginal tax rate. For a monthly medication cost of $259, that reduction can add up meaningfully over a year of treatment.

---

The Regulatory Context: Tirzepatide and the Shortage Designation

If you have looked into compounded tirzepatide, you may have encountered conflicting information about whether it is currently available. This reflects a real and evolving regulatory situation worth understanding.

Tirzepatide was added to the FDA drug shortage list in 2023 as demand for Mounjaro and Zepbound outpaced supply. During an active shortage, compounding pharmacies can legally prepare a compounded version of the drug to meet patient needs. Many telehealth platforms began offering compounded tirzepatide during this period.

In early 2025, the FDA removed Mounjaro and Zepbound from the drug shortage list, finding that supply had caught up with demand. This triggered a period of uncertainty for compounding pharmacies, as the shortage-based authority to compound tirzepatide became less clear. The situation has been subject to regulatory guidance, industry legal challenges, and ongoing interpretation by the compounding community.

If you are considering compounded tirzepatide, it is worth asking your provider directly about their pharmacy's current regulatory standing and whether they are operating within applicable FDA guidelines. Legitimate providers are transparent about this.

---

What to Do When Insurance Will Not Cover Tirzepatide

If your plan excludes Zepbound for weight management, or if you are uninsured, you are not out of options.

Option 1: Appeal a denial. If your plan technically covers anti-obesity medications but your prior authorization was denied, file an appeal. Studies of prior authorization appeals suggest first-level appeals succeed in roughly 40 percent of cases when providers submit additional supporting documentation. This is meaningful enough to make the attempt.

Option 2: Eli Lilly savings programs. For commercially insured patients with coverage but high cost-sharing, savings cards can reduce out-of-pocket costs. Check current eligibility terms through official Lilly channels.

Option 3: Compounded tirzepatide through a licensed telehealth provider. Compounded tirzepatide, prepared by a licensed 503A compounding pharmacy based on an individual prescription from a licensed provider, is available through telehealth platforms at substantially lower cost than brand-name Zepbound. Insurance does not cover compounded medications, but the direct cost is a fraction of the brand-name list price.

Telehealth platforms offering compounded tirzepatide typically include all-inclusive pricing covering medical consultation, prescribed medication, and shipping with no separate billing at the pharmacy. See the current pricing page for up-to-date cost information.

---

Cost Comparison: Insured vs. Out-of-Pocket vs. Compounded

Here is a realistic picture of tirzepatide costs under different scenarios in 2026:

For patients without commercial coverage of Zepbound, the out-of-pocket math often makes compounded tirzepatide through a transparent telehealth provider the more predictable and accessible option.

---

Compounded Tirzepatide: Key Facts Before You Choose This Path

Compounded tirzepatide is not the same as Mounjaro or Zepbound. A few important points for anyone considering this route:

It is not FDA-approved. Compounded medications are prepared under a different regulatory pathway than manufactured drugs. The FDA has not reviewed compounded tirzepatide for safety, efficacy, or quality. Any legitimate provider will disclose this clearly.

A valid prescription from a licensed provider is required. You cannot obtain compounded tirzepatide without a real medical evaluation. Platforms offering to sell it without a complete provider evaluation are operating outside the law.

Pharmacy accreditation matters. Ask specifically which pharmacy fills your prescription and whether it is 503A accredited. A credible provider will answer this directly.

The clinical evidence base. Published tirzepatide efficacy data comes from branded, FDA-approved Mounjaro and Zepbound studied in controlled trials. SURMOUNT-1 demonstrated 22.5 percent average weight loss at 72 weeks with the 15mg dose in non-diabetic participants. Compounded tirzepatide has not undergone equivalent independent clinical testing. Individual outcomes vary.

For patients who cannot access brand-name Zepbound due to insurance gaps, compounded alternatives through a vetted, compliant provider offer a practical path. The key is choosing a provider that is honest about what compounded medications are and are not.

---

Frequently Asked Questions

Does insurance cover Mounjaro? Most commercial insurance plans cover Mounjaro when prescribed for type 2 diabetes, subject to prior authorization. If you do not have a T2D diagnosis, coverage for Mounjaro as a weight loss treatment is generally not available through insurance.

Does insurance cover Zepbound? Some commercial plans cover Zepbound for weight management, but fewer than one in three commercial plans include anti-obesity medications. Prior authorization, BMI thresholds, and step therapy requirements typically apply. Check your specific plan's formulary.

Does Medicare cover tirzepatide for weight loss? No. Medicare Part D does not cover Zepbound for weight loss purposes as of 2026. Unlike Wegovy, which received an FDA label update for cardiovascular risk reduction that allowed CMS coverage expansion, Zepbound does not currently have a comparable FDA cardiovascular indication. Mounjaro is covered under Part D for Medicare beneficiaries with type 2 diabetes.

What if my prior authorization is denied? You have the right to appeal. Ask your provider to submit a detailed medical necessity letter with additional clinical documentation. First-level appeals succeed more often than patients expect when providers advocate actively.

Is compounded tirzepatide covered by insurance? No. Compounded medications are not covered by insurance because they are not FDA-approved standardized drug products. They are prepared per individual prescription by licensed compounding pharmacies. The direct cost of compounded tirzepatide through providers like Prescriva is significantly lower than out-of-pocket brand-name pricing.

Can I use my HSA or FSA for compounded tirzepatide? Generally yes, provided you have a valid prescription from a licensed provider. Prescription medications are eligible expenses under IRS rules for both HSAs and FSAs. Confirm with your plan administrator before submitting.

---

Getting Started

Navigating tirzepatide insurance is genuinely complicated. Some people find workable coverage for Mounjaro through their T2D diagnosis. Many others seeking Zepbound for weight management run into dead ends.

If you are among those for whom insurance is not a viable path, compounded tirzepatide through a licensed, transparent telehealth provider is a practical alternative. Prescriva connects you with licensed healthcare providers who evaluate whether a compounded weight management program is appropriate for your individual health situation. If treatment is right for you, your prescription is filled by a licensed compounding pharmacy and shipped to your home.

[Check your eligibility](/get-started) to connect with a licensed provider.

---

Disclaimers

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before starting any medication or treatment program.

Compounding Disclaimer: Compounded tirzepatide is not an FDA-approved medication. Compounded medications are not reviewed by the FDA for safety, efficacy, or quality. Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products (Mounjaro or Zepbound).

Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.

Brand Disclaimer: Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.

---

Sources

1. Rosenstock J, et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1). *Lancet.* 2021;398(10295):143-155. [PMID: 34186022](https://pubmed.ncbi.nlm.nih.gov/34186022/)
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). *New England Journal of Medicine.* 2022;387(3):205-216. [PMID: 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)
3. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT). *New England Journal of Medicine.* 2025. [PMID: 41406444](https://pubmed.ncbi.nlm.nih.gov/41406444/)
4. Dusetzina SB, et al. Coverage of Obesity Medications in Medicare Part D. *Health Affairs.* 2023. [DOI: 10.1377/hlthaff.2023.01057](https://www.healthaffairs.org/doi/10.1377/hlthaff.2023.01057)
5. Bray GA, et al. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obesity Reviews.* 2017;18(7):715-723. [PMID: 28489290](https://pubmed.ncbi.nlm.nih.gov/28489290/)
6. Centers for Medicare and Medicaid Services. Medicare Part D Coverage of Anti-Obesity Medications. CMS Guidance Document. 2024.
7. FDA. Zepbound (tirzepatide) Prescribing Information. 2023. [fda.gov](https://www.fda.gov)
8. FDA. Mounjaro (tirzepatide) Prescribing Information. 2022. [fda.gov](https://www.fda.gov)